Session Name: B-cell / Antibody /Autoimmunity
Session Date & Time: None. Available on demand.
*Purpose: TLR-Bregs were defined by our group as B cells generated in vitro. They have demonstrated the ability to inhibit CD4 T cell proliferation. Since CD8 T cells are also major players in rejection of organ transplants, the present report explores the mechanisms by which TLR-Breg suppression may differentially affects CD4 and CD8 T cells in a transplantation setting.
*Methods: B6 TLR-Bregs and OB1 TLR-Bregs were generated from B cells isolated from C57BL/6 and transgenic OB1 mice (B cell receptor specific to ovalbumin, OVA). In vitro MLR was set up in co-culture of CFSE-labeled CD8+ T cells (OVA-specific) as responders, irradiated OVA splenic cells as stimulators, and OB1 TLR-Bregs as suppressors. For in vivo suppression experiments, CD8 T cells were adoptively transferred to B6 underwent OVA skin graft, with or without B6 or OB1 TLR-Bregs. Cells from draining lymph nodes (DLN), non-draining lymph nodes (N-DLN), and spleen (SP) were harvested and analyzed by flow cytometry. The combination of anti-CD8 mAb and OB1 TLR-Bregs were administrated to check skin graft survival.
*Results: In vitro assays showed that OB1 TLR-Bregs suppress CD8+T cell proliferation and INF-γ production (p<0.05, vs control). In contrast to previous results showing that CD4+ T cells were concentrated in DLN, CD8+ T cells were not only found in the DLN, but also in the N-DLN and spleen (Figure 1). Suppression assays in vivo confirmed the inability of either B6 or OBI TLR-Bregs to inhibit CD8+ T cell proliferation, positive controls of proliferation were at 79.9%±3.8% and had no significant difference with Bregs treatment (64.7%±17.3%, Figure 2). Importantly, the in vivo depletion of CD8+T cells in mice treated with OB1 TLR-Bregs (61 days) did not significantly prolong graft survival than OB1 TLR-Bregs alone treatment (38 days).
*Conclusions: The lack of TLR-Breg control over CD8+ T cell proliferation may result from a more disperse lymphoid tissue distribution of these cells as compared to that of CD4+ T cells. Collectively, these data indicate that ex-vivo generated Bregs promote prolongation of graft survival, mainly by downregulating CD4+ helper T cell proliferation, which in turn may curtail graft-specific CD8 reactivity. Additional studies will be required to identify potential therapeutic targets to improve graft survival.
To cite this abstract in AMA style:Huai G, Lee K, Deng K, Fu Q, Rickert CG, Deng S, LeGuern C, Markmann JF. Donor-specific Regulatory B Cells Prolong Skin Graft Survival by Preventing the Proliferation of Donor-specific CD4 Helper but Not of CD8 Effector T Cells [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/donor-specific-regulatory-b-cells-prolong-skin-graft-survival-by-preventing-the-proliferation-of-donor-specific-cd4-helper-but-not-of-cd8-effector-t-cells/. Accessed June 18, 2021.
« Back to 2021 American Transplant Congress